Source - RNS
RNS Number : 2292J
Vectura Group plc
07 September 2016
 

 

 

Vectura Group plc

Results of the Annual General Meeting held on 7 September 2016 at the offices of Covington & Burling LLP, 265 Strand, London WC2R 1BH. 

Chippenham, UK, 7 September 2016: Vectura Group plc (LSE: VEC; "Vectura" or "the Company"), announces that all resolutions proposed to shareholders at its Annual General Meeting held today were duly passed on a poll, the results of which are set out below:

 

Resolution

Votes for

% of votes cast

Votes against

% of votes cast

Votes withheld*

 1

To receive the Annual Report & Accounts to 31 March 2016

551,934,169

97.78

12,512,658

2.22

373,172

2

To approve the Directors' Remuneration Report

537,667,257

95.24

26,853,225

4.76

299,517

3

To elect James Ward-Lilley

559,939,018

99.19

4,564,596

0.81

316,385

4

To elect Frank Condella

403,554,380

74.08

141,183,513

25.92

20,082,106

5

To elect Andrew Derodra

554,739,795

98.27

9,764,639

1.73

315,565

6

To elect Dr Thomas Werner

553,561,225

98.87

6,343,596

1.13

4,915,051

7

To re-elect Bruno Angelici

529,239,785

97.10

15,792,009

2.90

19,788,205

8

To re-elect Dr T Phillips

559,960,406

99.20

4,541,963

0.80

317,630

9

To re-elect Dr Susan Foden

552,754,573

98.73

7,133,740

1.27

4,931,686

10

To re-elect Neil Warner

558,720,725

99.79

1,166,583

0.21

4,932,691

11

To re-elect Dr P Andersson

561,935,088

99.55

2,566,283

0.45

318,453

12

To re-appoint Deloitte LLP as Auditor

548,806,722

98.17

10,255,786

1.83

5,757,491

13

To authorise the Directors to determine the remuneration of the Auditor

539,539,681

96.51

19,538,961

3.49

5,741,357

14

To authorise the Directors to amend rules of the Vectura Group PLC Share Incentive Plan and establish similar plans overseas

557,266,537

98.68

7,447,299

1.32

104,300

15

To grant the Directors authority to allot shares

546,290,810

96.74

18,431,862

3.26

91,611

16

To grant the Directors authority to disapply pre-emption rights

558,267,446

98.84

6,531,790

1.16

20,736

17

To grant the Directors authority to disapply pre-emption rights in respect of additional shares allotted for an acquisition or capital investment

521,881,705

92.41

42,844,305

7.59

93,989

18

To authorise the calling of General Meetings on 14 days' notice

550,234,593

97.47

14,292,724

2.53

292,681

 

*NB: The percentage of votes cast for and against excludes withheld votes.

Enquiries:

 

 

Vectura Group plc

+44 (0)1249 667700

 

 

John Murphy

Company Secretary

 

 

One Prospect West

Chippenham

Wiltshire SN14 6FH

 

 

Citigate Dewe Rogerson

+44 (0)20 7638 9571

David Dible / Mark Swallow

 

 

 

Notes for Editors:

About Vectura

Vectura, a FTSE250 company listed on the London Stock Exchange (LSE: VEC), is an industry-leading inhaled airways disease focused business with proprietary formulation and devices across DPI, pMDI and smart nebulisation platforms. With our extensive range of technologies, capabilities and collaborations, we believe we can become a leader in the development of inhalation products, increasing our ability to help patients suffering from respiratory diseases.  In June 2016 Vectura completed a merger with Skyepharma PLC.

Vectura has seven inhaled, four non-inhaled and ten oral products marketed by partners with growing global royalty streams, and a portfolio of drugs in clinical development, a number of which have licence agreements with several global pharmaceutical and biotechnology companies including Hikma, Novartis, Sandoz, Mundipharma, Kyorin, Baxter, GSK, UCB, Ablynx, Grifols, Chiesi, Almirall, Janssen, and Tianjin KingYork.

For further information, please visit Vectura's website at www.vectura.com.

 


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
RAGLRMJTMBAMBLF